Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17422199 | 0.74 | LMNA (0.32) | — | |
| SCHEMBL17422305 | 0.70 | LMNA (0.30) | — | |
| SCHEMBL5328793 | 0.66 | LMNA (0.34) | — | |
| SCHEMBL7753780 | 0.61 | LMNA (0.52) | CA12CA2CA9 | |
| SCHEMBL9902644 | 0.61 | LMNA (0.62) | — | |
| SCHEMBL17422235 | 0.61 | CA12 (0.36) | CA12CA2CA9 | |
| SCHEMBL21444533 | 0.58 | GAA (0.32) | — | |
| SCHEMBL4939489 | 0.57 | LMNA (0.33) | — | |
| SCHEMBL12896114 | 0.54 | GCK (0.38) | — | |
| SCHEMBL28316196 | 0.54 | LMNA (0.52) | CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034152-A1 | METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE | ST PHARM CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| EP-4442687-A1 | METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE | ST Pharm Co., Ltd. (KR) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024191138-A1 | COMBINATION THERAPY OF TRIAZOLOPYRIMIDINONE DERIVATIVE AND MEK INHIBITOR | 에스티팜 주식회사 | 2024-09-19 | — | — | WO | disclosed |
| WO-2024191139-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF KRAS MUTANT CANCER | 에스티팜 주식회사 | 2024-09-19 | — | — | WO | disclosed |
| CN-118284609-A | Process for preparing triazolopyrimidinone derivatives | ST制药株式会社 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023101048-A1 | METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE | 에스티팜 주식회사 | 2023-06-08 | — | — | WO | disclosed |
| EP-3166945-B1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO LTD (KR) | 2019-10-09 | — | — | EP | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
| EP-3166945-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST Pharm Co. Ltd. (KR) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016006974-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TNKS, TPI1 | CA12 3686/4885CA2 1121/4885CA9 1405/4885 |
| US-20250034152-A1 | METHOD FOR PREPARING TRIAZOLOPYRIMIDINONE DERIVATIVE | TNKS1BP1, TNKS, TPI1 | CA12 4356/4885CA2 1961/4885CA9 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.